Sodium-glucose co-transporter-2 (SGLT2) inhibitors have emerged as a promising therapeutic class in the management of heart failure, offering benefits such as reduced mortality, fewer heart failure hospitalisations and improved cardiac function [4–8]. Here, SLC5A2 is linked to heart failure.